SynOx Therapeutics Limited is a Dublin-based, late clinical-stage biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders.

TGCT is a rare, non-malignant but aggressively growing tumour of the synovium located in the joints and caused by excessive production of CSF-1. It is a chronically debilitating disease for patients causing loss of function of the affected joints, pain, stiffness and limited range of motion. Emactuzumab specifically inhibits CSF-1R and earlier clinical work in TGCT showed it to be a highly effective, next-generation therapy with a short treatment cycle, rapid onset of action and long duration of response.

SynOx is conducting a registrational Phase 3 clinical trial, named TANGENT to evaluate the efficacy and safety of emactuzumab in patients with TGCT.